In recent decades, fetal-tissue research wasn’t much of a political issue, at least not at the national level, because there are no medical or scientific reasons to curtail the area of study. After an abortion, fetal tissue can either be discarded or used in potentially life-saving medical research. Reproductive rights can be a contentious issue for a variety of reasons, but this facet of the debate seems uncomplicated.
It’s precisely why support for fetal-tissue research has been broad and bipartisan for many years. When Congress passed a law authorizing the research in 1993, the vote in the Senate was 93 to 4.
But as regular readers know, Donald Trump’s administration took the research in a regressive direction last year, ending fetal-tissue research within the National Institutes of Health and scrapping research contracts.
The step backward is suddenly relevant anew. The Washington Post reported last week:
A senior scientist at a government biomedical research laboratory has been thwarted in his efforts to conduct experiments on possible treatments for the new coronavirus because of the Trump administration’s restrictions on research with human fetal tissue. The scientist, Kim Hasenkrug, an immunologist at the National Institutes of Health’s Rocky Mountain Laboratories in Montana, has been appealing for nearly a month to top NIH officials, arguing that the pandemic warrants an exemption to a ban imposed last year prohibiting government researchers from using tissue from abortions in their work.
The article quoted Irving Weissman, a leading stem cell researcher at Stanford University, who explained that the NIH’s Hasenkrug “is one of the world experts in immune responses to persistent viral infection,” and though we don’t know whether his line of inquiry would help address the coronavirus crisis, “it’s stupid not to try.”









